Power Moves: With new funding round, Audacious Inquiry adds to C-suite, board

Power Moves is a column where we chart the comings and goings of talent across the region. Got a new hire, new gig or promotion? Tell us: baltimore@technical.ly.

---

Health IT firm Audacious Inquiry (Ai) is adding three executives to its senior leadership team, as well as a new board member. This comes as the Catonsville-based company completed a new round of growth equity financing, led by Minneapolis-based TT Capital Partners, along with Frist Cressey Venture, a Nashville firm cofounded by former U.S. Sen. Bill Frist and Baltimore-based ABS Capital Partners.

The new C-level appointments:

• Edwin Miller joined as chief product officer. Miller is cofounder of Bethesda-based health tech company Aledade.
• Sunil Chandran joined as chief technology officer. He previously served as CTO of Herdon, Virginia-based franchise management software company FranConnect and VP of engineering at SAP SuccessFactors.
• Marie Klok Crump joined as chief marketing officer. She previously was a cofounder of DATUM, a data governance company acquired in 2018.

Additionally, TTCP partner Ryan Engle is joining the company’s board, and Frist Cressey Ventures partner Navid Farzad joined as a board observer.

“There is a clear need to address the fundamental lack of effective care transitions and sub-optimal patient outcomes that could be improved by more timely and actionable healthcare data, and Audacious Inquiry’s differentiated capabilities, years of experience, and strong leadership team uniquely position them to create a more connected and effective healthcare system,” Engle said in a statement.

It’s a thrilling time to be a part of @A_INQ team! With these excellent new additions to our senior leadership team and new funding, the future of #HealthIT is bright! https://t.co/rpBq6gT0Hy

— Bill Frist, M.D. (@bfrist) October 7, 2020

Ai is a nominee for Growth Company of the Year in the 2020 Technical.ly Awards (with winners to be announced this afternoon during the BIW Innovation Celebration). Check out more about the data tools they applied in response to the pandemic.

###

Downtown venture studio Early Charm Ventures has a new applications scientist.

Dr. Olumide Kayode joined the team bringing biology research experience Cancer Research Training Program at the National Cancer Institute and the Mayo Clinic Graduate School.

Spark Baltimore-based Early Charm has a portfolio of companies that are commercializing technologies in several categories. Many of these involve advanced understanding of proteins. That’s where Dr. Kayode will focus initially, in particular the drug discovery company Revolve Technologies.

###

Advanced materials company Pixelligent appointed Dr. Robert Fleming to its technical advisory board.

Fleming is currently the VP for research and technology at Emeryville, California-based biotech company Zymergen. Previously, he led development of the world’s first full-color, video retro-reflective display at CLEARlink Displays, and worked at 3M for a dozen years in management and R&D roles.

Pixelligent, based off Holabird Avenue near the city-county line, creates compounds that are designed to improve performance for lighting, AR/VR, displays and optical sensors. After 18 months developing new products, the company is planning new releases in the coming weeks.

“I have worked with Pixelligent for years, and I know they have the best-in-class high-index materials on the market,” Dr. Fleming said in a statement. “I’m looking forward to bringing my perspective as a former customer to help Pixelligent execute on their formulation strategy.

###

Tech and operations advisory firm Think promoted Joe Poling to director of client solutions. This role includes assisting clients with organizational transformation, operational effectiveness, innovation, demand management and growth.

Poling has 25 years of experience with tech companies, including On-Site Computer Services, Inc., Eyecon, LLC and a spinoff of Hunt Valley-based Sylvan Learning called eSylvan.